We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Dirui Industrial

DIRUI Industrial Co., Ltd provides laboratory equipment and clinical diagnostic reagents for the in-vitro diagnostic ... read more Featured Products: More products

Download Mobile App





DIRUI Presents High-End Diagnostic Systems for Hospitals and High-Volume Labs at EUROMEDLAB 2022

By Carolyn Moody, RN - News Editor
Posted on 12 Apr 2022
Print article
Image: DIRUI presented its high-end analyzers at EUROMEDLAB (Photo courtesy of DIRUI)
Image: DIRUI presented its high-end analyzers at EUROMEDLAB (Photo courtesy of DIRUI)

DIRUI Industrial Co., Ltd. (Jilin, China) presented its high-end diagnostic systems, including hematology, chemiluminescence immunoassay, chemistry and urinanalysis analyzers, for hospitals and high-volume labs at EUROMEDLAB 2022.

DIRUI demonstrated its BF-7200Plus automatic hematology analysis system which has a maximum throughput of 480 tests per hour and measures 37 parameters (including RET detection), five scattergrams and two histograms. It performs optical analysis for WBC measurement and comes with pathology and morphology abnormality alarms. DIRUI also demonstrated its new CM180 chemiluminescence immunoassay analyzer with a throughput of up to 180 tests/hour and walk-away time of up to 2.5 hours. The CM180 has time to first result of only 15 minutes and allows 25 items to be tested at the same time. Featuring a user-friendly design to keep test results accurate and reliable, the CM180 analyzer provides the best solution for laboratory chemiluminescence immunoassay.

Also on display at EUROMEDLAB 2022 was DIRUI’s CS-T240Plus automatic chemistry analyzer which offers the ultimate in convenience, performance and confidence for small to medium size laboratories. The powerful desktop analyzer has a maximum throughput of 240 tests/hour at constant speed and 480 tests/hour for ISE. It uses whole blood samples to test for HbA1c, ensuring more accurate results and has a water consumption of only three liters per hour. This automated random access clinical chemistry analyzer can be easily integrated with any type of laboratories for routine, emergency analysis. In addition, DIRUI showcased its MUS-3600 automatic urinanalysis system with a flexible combination of modules and super fast detection speed. It has a throughput of up to 480 tests per hour (for hybrid) and allows up to 580 urine samples to be loaded at one time. Using leading detection methodologies, the MUS-3600 can provide objective and quantitative report information, clear and visible particle image information, and three key clinical information - red blood cell morphology information, urinary tract infection information, and urine culture information.

Related Links:
DIRUI Industrial Co., Ltd. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.